Progress of interleukin-12 in treatment of solid tumors
10.3760/cma.j.cn115355-20211113-00512
- VernacularTitle:白细胞介素12在实体瘤治疗中的研究进展
- Author:
Kexin WU
1
;
Fentian CHEN
;
Wenxin LUO
Author Information
1. 厦门大学生命科学学院 国家传染病诊断试剂与疫苗工程研究中心，厦门 361102
- Keywords:
Interleukin-12;
Neoplasms;
Immunotherapy;
Tumor microenvironment
- From:
Cancer Research and Clinic
2022;34(8):627-630
- CountryChina
- Language:Chinese
-
Abstract:
Interleukin-12 (IL-12) is a pro-inflammatory cytokine derived from antigen-presenting cells. IL-12 has a variety of effector mechanisms such as promoting T cells proliferation and cytotoxicity, inducing T cells and NK cells to secrete interferon-γ (IFN-γ), etc. IL-12 shows significant anti-tumor effect in preclinical stage and is quickly used in clinic, but its systemic administration has serious dose-limiting toxicity. At present, most of the research is about the topical use of IL-12 to reduce systemic toxicity, change tumor microenvironment and activate immune system. This article reviews the research progress and clinical trials of IL-12 in the treatment of solid tumors in recent years.
